Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
Key Highlights
- ➤Cash CHF 57.5 million as of September 30, 2026, funds operations into late 2027
- ➤Workforce reduction of up to 55 positions, approximately 44% of current workforce
- ➤MP0712 dose level 2 fully recruited; initial safety data due December 2026
- ➤2026 operating expenses forecast at CHF 50-55 million, including CHF 5 million non-cash costs
- ➤Molecular Partners deepens strategic focus on radiopharmaceuticals and Radio-DARPin programs
Expert Statements
Patrick Amstutz, CEO of Molecular Partners
“This third quarter marked a decisive step in Molecular Partners’ transformation into a dedicated radiopharmaceuticals company. Encouraged by the emerging Phase 1/2a data from MP0712, our DLL3 Radio-DARPin for SCLC, we believe now is the time to focus on targeted radiotherapy. With efficacy data expected in 2027, we will continue to execute our lead asset MP0712 and advance our clinical Radio-DARPin programs to deliver value to shareholders and meaningful benefit to cancer patients,”
* Dosing ongoing in fully recruited dose level 2 of MP0712 Phase 1/2a study; initial safety data to be presented at North America Conference on Lung Cancer in December 2026, efficacy data expected in 2027 * Emerging clinical data from lead Radio-DARPin candidate MP0712 enables strategic focus on radiopharmaceuticals * Streamlining of organization, in line with corporate focus, to advance Radio-DARPin programs * Cash position of CHF 57.5 million (USD ~69 million) as of September 30, 2026, expected to fund operations into late 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics, (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the third quarter of 2026, as well as a deepened focus on radiopharmaceuticals and streamlining of its resources.
Get started
Create a free account to read the full story.